Who
Charles S. Fuchs
President, R&D
Company insider
Files Form 4 as: President, R&D, Erasca; Director, CytomX Therapeutics.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 23 Oct 2017
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,300,000 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,300,000 at $0.00 | filing |
| 24 Jul 2026filed 30 Jul 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —118,000 at $0.00 | filing |
| 24 Jul 2026filed 30 Jul 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —118,000 at $0.00 | filing |
| 17 Jun 2020filed 17 Jun 2020 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 19 Jun 2019filed 21 Jun 2019 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 13 Jun 2018filed 15 Jun 2018 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 23 Oct 2017filed 24 Oct 2017 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.